Recent

% | $
Quotes you view appear here for quick access.

Stellar Biotechnologies, Inc. Message Board

stellarklhgold 11 posts  |  Last Activity: Jul 17, 2015 8:02 AM Member since: Aug 12, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • stellarklhgold stellarklhgold Jul 17, 2015 8:02 AM Flag

    haha that is funny

  • stellarklhgold stellarklhgold Jul 4, 2015 8:13 PM Flag

    even old ones too!

  • Reply to

    The Promise of Preventive Cancer Vaccines

    by highflier2go Jun 17, 2015 7:21 PM
    stellarklhgold stellarklhgold Jun 18, 2015 6:50 AM Flag

    Excellent...bump

  • stellarklhgold stellarklhgold Jun 17, 2015 1:23 PM Flag

    Keyhole Limpet Hemocyanin (KLH) is a primary component of Neovacs’ proprietary Kinoid immunotherapy technology. Which is supplied by Stellar.

  • stellarklhgold stellarklhgold Jun 16, 2015 9:10 PM Flag

    A Kinoid is obtained by chemically linking the cytokine of interest to a foreign carrier protein, KLH (Keyhole Limpet Hemocyanin), and then treating the resultant compound to inactivate the cytokine.

  • Neovacs Initiates Clinical Program in Dermatomyositis


    June 16, 2015 02:15 ET | Source: Neovacs, Inc.
    Extension of IFNα-Kinoid program to include Dermatomyositis
    Formation of Clinical Advisory Board
    Anticipated trial launch early 2016
    PARIS and BOSTON, June 16, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the launch of its clinical development program in Dermatomyositis (DM), an orphan skin and muscular condition with significant unmet medical need.

    Neovacs is extending its IFNα-Kinoid clinical program beyond lupus to include adult and pediatric DM – an indication where a positive IFNα signature plays a decisive role1. The decision follows a recommendation earlier this year by the Company's Scientific Advisory Board to pursue IFNα-Kinoid as a potential treatment for DM and extensive due diligence in researching IFN-related diseases that could benefit from this treatment modality. Neovacs plans to conduct a multicentric phase I/IIa trial of IFNα-Kinoid in adult DM in 15 patients which is anticipated to launch in early 2016 in France and other European countries.

    "Dermatomyositis demonstrates a promising therapeutic candidate pipeline expansion, given the demonstrated role of IFNα in this auto-immune disease. As DM is an orphan condition, this is also an opportunity to bring needed relief to thousands of patients, most of them children, for whom there is currently no satisfactory biotherapy," commented Miguel Sieler, CEO of Neovacs. "We believe that the IFNα-Kinoid in DM will be a development driver for Neovacs, with a limited impact on expenditures. Neovacs will apply for grants dedicated to rare diseases to support the funding of the DM program."

  • Reply to

    The Road to Ruin

    by druggy35 Jun 13, 2015 10:18 AM
    stellarklhgold stellarklhgold Jun 15, 2015 8:33 PM Flag

    INSIDER PURCHASES ----Insiders have purchased shares

    Date Name: Shares Transaction Value
    12/31/14 Mark W. Schwartz,
    Director, President and Chief Executive Officer 3,846 Other at $1.28 per share. $4,923
    12/31/14 Ryan Dunlap,
    Vice President, Chief Financial Officer, Controller and Corporate Secretary 3,846 Other at $1.28 per share. $4,923
    06/30/14 Mark J. Ahn,
    Director, Chief Executive Officer and President 2,461 Other at $2.60 per share. $6,399
    06/30/14 Brian L. Hamilton,
    Executive Vice President and Chief Medical Officer 2,461 Other at $2.60 per share. $6,399
    06/30/14 Mark W. Schwartz,
    Executive Vice President and Chief Operating Officer 2,461 Other at $2.60 per share. $6,399
    06/30/14 Ryan Dunlap,
    Director of Finance, Controller, Corporate Secretary and Principal Accounting Officer 2,461 Other at $2.60 per share. $6,399
    02/03/14 Sanford J. Hillsberg,
    Chairman of the Board 10,000 Gift at $0.00 per share. $0
    02/03/14 Stephen S. Galliker,
    Independent Director 50,000 Option Exercise at $1.71 per share. $85,500
    02/03/14 Stephen S. Galliker,
    Independent Director 50,000 Option Exercise at $2.31 per share. $115,500
    02/03/14 Stephen S. Galliker,
    Independent Director 100,000 Option Exercise at $1.18 per share. $118,000
    02/03/14 Stephen S. Galliker,
    Independent Director 50,000 Option Exercise at $0.85 per share. $42,500
    02/03/14 Stephen S. Galliker,
    Independent Director 50,000 Option Exercise at $0.72 per share. $36,000
    01/30/14 Sanford J. Hillsberg,
    Chairman of the Board 15,000 Gift at $0.00 per share. $0
    01/30/14 Sanford J. Hillsberg,
    Chairman of the Board 50,000 Option Exercise at $1.71 per share. $85,500

  • stellarklhgold stellarklhgold Jun 11, 2015 8:42 PM Flag

    HAHA Great call in April about single digits...keeps going up up up

  • Reply to

    Listen to Wilbur Ross this morning on CNBC

    by canadaallan Jun 8, 2015 10:39 AM
    stellarklhgold stellarklhgold Jun 9, 2015 6:49 AM Flag

    Stansberry rec

  • Reply to

    So sad ...but funny.

    by xeroiszero Jun 1, 2015 5:28 PM
    stellarklhgold stellarklhgold Jun 2, 2015 9:28 PM Flag

    Not justifying their bad results..just saying the site has negative comments about most if not all companies...you are wrapped too tight dude

  • Reply to

    So sad ...but funny.

    by xeroiszero Jun 1, 2015 5:28 PM
    stellarklhgold stellarklhgold Jun 2, 2015 6:38 AM Flag

    google search just about any company..Apple, Target, Kohls etc and MOST comments are negative....not just Xerox

SBOTF
0.8951+0.2841(+46.50%)Aug 28 3:59 PMEDT